Annual report

Period2023-07-01 → 2024-06-30
Filed2024-09-27
StandardJapan GAAP
ConsolidatedYes
Data checks24 of 24 passed
Key figures · 145
MetricValuePeriodScopeSource row
Revenue¥5.2bn2023-07-01 → 2024-06-30Cons.Net sales
Revenue¥8.1bn2022-07-01 → 2023-06-30Cons.Net sales
Revenue¥9.3bn2021-07-01 → 2022-06-30dCons.Net sales (5-year summary)
Revenue¥8.9bn2020-07-01 → 2021-06-30dCons.Net sales (5-year summary)
Revenue¥9.3bn2019-07-01 → 2020-06-30dCons.Net sales (5-year summary)
Operating income−¥610m2023-07-01 → 2024-06-30Cons.Operating income
Operating income¥726m2022-07-01 → 2023-06-30Cons.Operating income
Ordinary income−¥566m2023-07-01 → 2024-06-30Cons.Ordinary income
Ordinary income¥727m2022-07-01 → 2023-06-30Cons.Ordinary income
Ordinary income¥1.3bn2021-07-01 → 2022-06-30dCons.Ordinary income loss (5-year summary)
Ordinary income¥920m2020-07-01 → 2021-06-30dCons.Ordinary income loss (5-year summary)
Ordinary income¥1.1bn2019-07-01 → 2020-06-30dCons.Ordinary income loss (5-year summary)
Profit before tax−¥615m2023-07-01 → 2024-06-30Cons.Income before income taxes
Profit before tax¥725m2022-07-01 → 2023-06-30Cons.Income before income taxes
Net income (owners)−¥662m2023-07-01 → 2024-06-30Cons.Profit loss attributable to owners of parent
Net income (owners)¥452m2022-07-01 → 2023-06-30Cons.Profit loss attributable to owners of parent
Net income (owners)¥810m2021-07-01 → 2022-06-30dCons.Profit loss attributable to owners of parent (5-year summary)
Net income (owners)¥562m2020-07-01 → 2021-06-30dCons.Profit loss attributable to owners of parent (5-year summary)
Net income (owners)¥732m2019-07-01 → 2020-06-30dCons.Profit loss attributable to owners of parent (5-year summary)
Net income−¥663m2023-07-01 → 2024-06-30Cons.Profit loss
Net income¥456m2022-07-01 → 2023-06-30Cons.Profit loss
Total assets¥6.9bnat 2024-06-30Cons.Assets
Total assets¥8.2bnat 2023-06-30Cons.Assets
Total assets¥8.5bnat 2022-06-30dCons.Total assets (5-year summary)
Total assets¥7.1bnat 2021-06-30dCons.Total assets (5-year summary)
Total assets¥7.4bnat 2020-06-30dCons.Total assets (5-year summary)
Total liabilities¥697mat 2024-06-30Cons.Liabilities
Total liabilities¥1.1bnat 2023-06-30Cons.Liabilities
Net assets / equity¥6.2bnat 2024-06-30Cons.Net assets
Net assets / equity¥7.2bnat 2023-06-30Cons.Net assets
Net assets / equity¥6.8bnat 2022-06-30dCons.Net assets
Net assets / equity¥6.2bnat 2021-06-30dCons.Net assets (5-year summary)
Net assets / equity¥5.8bnat 2020-06-30dCons.Net assets (5-year summary)
Cash and deposits¥4.8bnat 2024-06-30Cons.Cash and deposits
Cash and deposits¥5.9bnat 2023-06-30Cons.Cash and deposits
Cash & equivalents¥4.8bnat 2024-06-30Cons.Cash and cash equivalents
Cash & equivalents¥5.9bnat 2023-06-30Cons.Cash and cash equivalents
Cash & equivalents¥6.0bnat 2022-06-30dCons.Cash and cash equivalents
Cash & equivalents¥4.3bnat 2021-06-30dCons.Cash and cash equivalents (5-year summary)
Cash & equivalents¥4.5bnat 2020-06-30dCons.Cash and cash equivalents (5-year summary)
Operating cash flow−¥881m2023-07-01 → 2024-06-30Cons.Net cash provided by used in operating activities
Operating cash flow−¥102m2022-07-01 → 2023-06-30Cons.Net cash provided by used in operating activities
Operating cash flow¥2.1bn2021-07-01 → 2022-06-30dCons.Net cash provided by used in operating activities (5-year summary)
Operating cash flow−¥107m2020-07-01 → 2021-06-30dCons.Net cash provided by used in operating activities (5-year summary)
Operating cash flow¥830m2019-07-01 → 2020-06-30dCons.Net cash provided by used in operating activities (5-year summary)
Investing cash flow−¥14m2023-07-01 → 2024-06-30Cons.Net cash provided by used in investment activities
Investing cash flow¥160m2022-07-01 → 2023-06-30Cons.Net cash provided by used in investment activities
Investing cash flow−¥245m2021-07-01 → 2022-06-30dCons.Net cash provided by used in investing activities (5-year summary)
Investing cash flow−¥25m2020-07-01 → 2021-06-30dCons.Net cash provided by used in investing activities (5-year summary)
Investing cash flow¥693m2019-07-01 → 2020-06-30dCons.Net cash provided by used in investing activities (5-year summary)
Financing cash flow−¥261m2023-07-01 → 2024-06-30Cons.Net cash provided by used in financing activities
Financing cash flow−¥130m2022-07-01 → 2023-06-30Cons.Net cash provided by used in financing activities
Financing cash flow−¥130m2021-07-01 → 2022-06-30dCons.Net cash provided by used in financing activities (5-year summary)
Financing cash flow−¥131m2020-07-01 → 2021-06-30dCons.Net cash provided by used in financing activities (5-year summary)
Financing cash flow−¥103m2019-07-01 → 2020-06-30dCons.Net cash provided by used in financing activities (5-year summary)
EPS (basic)¥-25.322023-07-01 → 2024-06-30Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥17.272022-07-01 → 2023-06-30Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥30.952021-07-01 → 2022-06-30dCons.Basic earnings loss per share (5-year summary)
EPS (basic)¥21.492020-07-01 → 2021-06-30dCons.Basic earnings loss per share (5-year summary)
EPS (basic)¥27.972019-07-01 → 2020-06-30dCons.Basic earnings loss per share (5-year summary)
Net assets per share¥238.28at 2024-06-30Cons.Net assets per share (5-year summary)
Net assets per share¥266.41at 2023-06-30Cons.Net assets per share (5-year summary)
Net assets per share¥254.14at 2022-06-30dCons.Net assets per share (5-year summary)
Net assets per share¥230.88at 2021-06-30dCons.Net assets per share (5-year summary)
Net assets per share¥214.39at 2020-06-30dCons.Net assets per share (5-year summary)
Equity ratio89.7%at 2024-06-30Cons.Equity to asset ratio (5-year summary)
Equity ratio84.6%at 2023-06-30Cons.Equity to asset ratio (5-year summary)
Equity ratio78.3%at 2022-06-30dCons.Equity to asset ratio (5-year summary)
Equity ratio84.5%at 2021-06-30dCons.Equity to asset ratio (5-year summary)
Equity ratio75.7%at 2020-06-30dCons.Equity to asset ratio (5-year summary)
ROE6.6%2022-07-01 → 2023-06-30Cons.Rate of return on equity (5-year summary)
ROE12.8%2021-07-01 → 2022-06-30dCons.Rate of return on equity (5-year summary)
ROE9.7%2020-07-01 → 2021-06-30dCons.Rate of return on equity (5-year summary)
ROE13.8%2019-07-01 → 2020-06-30dCons.Rate of return on equity (5-year summary)
Employees90at 2024-06-30Cons.Number of employees
Employees98at 2023-06-30Cons.Number of employees
Employees100at 2022-06-30dCons.Number of employees
Employees104at 2021-06-30dCons.Number of employees
Employees105at 2020-06-30dCons.Number of employees
Revenue¥304m2023-07-01 → 2024-06-30StandaloneNet sales
Revenue¥377m2022-07-01 → 2023-06-30StandaloneNet sales
Revenue¥439m2021-07-01 → 2022-06-30dStandaloneNet sales (5-year summary)
Revenue¥425m2020-07-01 → 2021-06-30dStandaloneNet sales (5-year summary)
Revenue¥425m2019-07-01 → 2020-06-30dStandaloneNet sales (5-year summary)
Operating income−¥6m2023-07-01 → 2024-06-30StandaloneOperating income
Operating income¥81m2022-07-01 → 2023-06-30StandaloneOperating income
Ordinary income¥2m2023-07-01 → 2024-06-30StandaloneOrdinary income
Ordinary income¥87m2022-07-01 → 2023-06-30StandaloneOrdinary income
Ordinary income¥137m2021-07-01 → 2022-06-30dStandaloneOrdinary income loss (5-year summary)
Ordinary income¥132m2020-07-01 → 2021-06-30dStandaloneOrdinary income loss (5-year summary)
Ordinary income¥116m2019-07-01 → 2020-06-30dStandaloneOrdinary income loss (5-year summary)
Profit before tax−¥9m2023-07-01 → 2024-06-30StandaloneIncome before income taxes
Profit before tax¥87m2022-07-01 → 2023-06-30StandaloneIncome before income taxes
Net income−¥10m2023-07-01 → 2024-06-30StandaloneProfit loss
Net income¥142m2022-07-01 → 2023-06-30StandaloneProfit loss
Net income¥195m2021-07-01 → 2022-06-30dStandaloneNet income loss (5-year summary)
Net income¥288m2020-07-01 → 2021-06-30dStandaloneNet income loss (5-year summary)
Net income¥155m2019-07-01 → 2020-06-30dStandaloneNet income loss (5-year summary)
Total assets¥4.2bnat 2024-06-30StandaloneAssets
Total assets¥4.3bnat 2023-06-30StandaloneAssets
Total assets¥4.5bnat 2022-06-30dStandaloneTotal assets (5-year summary)
Total assets¥4.2bnat 2021-06-30dStandaloneTotal assets (5-year summary)
Total assets¥4.1bnat 2020-06-30dStandaloneTotal assets (5-year summary)
Total liabilities¥29mat 2024-06-30StandaloneLiabilities
Total liabilities¥21mat 2023-06-30StandaloneLiabilities
Net assets / equity¥4.1bnat 2024-06-30StandaloneNet assets
Net assets / equity¥4.3bnat 2023-06-30StandaloneNet assets
Net assets / equity¥4.3bnat 2022-06-30dStandaloneNet assets
Net assets / equity¥4.2bnat 2021-06-30dStandaloneNet assets (5-year summary)
Net assets / equity¥4.1bnat 2020-06-30dStandaloneNet assets (5-year summary)
Cash and deposits¥1.2bnat 2024-06-30StandaloneCash and deposits
Cash and deposits¥1.3bnat 2023-06-30StandaloneCash and deposits
EPS (basic)¥-0.42023-07-01 → 2024-06-30StandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥5.442022-07-01 → 2023-06-30StandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥7.472021-07-01 → 2022-06-30dStandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥11.022020-07-01 → 2021-06-30dStandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥5.912019-07-01 → 2020-06-30dStandaloneBasic earnings loss per share (5-year summary)
Dividend per share¥52022-07-01 → 2023-06-30StandaloneDividend paid per share (5-year summary)
Dividend per share¥52021-07-01 → 2022-06-30dStandaloneDividend paid per share (5-year summary)
Dividend per share¥52020-07-01 → 2021-06-30dStandaloneDividend paid per share (5-year summary)
Dividend per share¥52019-07-01 → 2020-06-30dStandaloneDividend paid per share (5-year summary)
Net assets per share¥158.55at 2024-06-30StandaloneNet assets per share (5-year summary)
Net assets per share¥163.95at 2023-06-30StandaloneNet assets per share (5-year summary)
Net assets per share¥163.52at 2022-06-30dStandaloneNet assets per share (5-year summary)
Net assets per share¥161.05at 2021-06-30dStandaloneNet assets per share (5-year summary)
Net assets per share¥155.03at 2020-06-30dStandaloneNet assets per share (5-year summary)
Equity ratio99.3%at 2024-06-30StandaloneEquity to asset ratio (5-year summary)
Equity ratio99.5%at 2023-06-30StandaloneEquity to asset ratio (5-year summary)
Equity ratio95.6%at 2022-06-30dStandaloneEquity to asset ratio (5-year summary)
Equity ratio99.5%at 2021-06-30dStandaloneEquity to asset ratio (5-year summary)
Equity ratio99.6%at 2020-06-30dStandaloneEquity to asset ratio (5-year summary)
ROE3.3%2022-07-01 → 2023-06-30StandaloneRate of return on equity (5-year summary)
ROE4.6%2021-07-01 → 2022-06-30dStandaloneRate of return on equity (5-year summary)
ROE7.0%2020-07-01 → 2021-06-30dStandaloneRate of return on equity (5-year summary)
ROE3.8%2019-07-01 → 2020-06-30dStandaloneRate of return on equity (5-year summary)
Shares issued26,158,200at 2024-06-30StandaloneTotal number of issued shares (5-year summary)
Shares issued26,158,200at 2023-06-30StandaloneTotal number of issued shares (5-year summary)
Shares issued26,158,200at 2022-06-30dStandaloneTotal number of issued shares (5-year summary)
Shares issued26,158,200at 2021-06-30dStandaloneTotal number of issued shares (5-year summary)
Shares issued26,158,200at 2020-06-30dStandaloneTotal number of issued shares (5-year summary)
Employees11at 2024-06-30StandaloneNumber of employees
Employees7at 2023-06-30StandaloneNumber of employees
Employees9at 2022-06-30dStandaloneNumber of employees
Employees8at 2021-06-30dStandaloneNumber of employees
Employees8at 2020-06-30dStandaloneNumber of employees

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 94
SegmentItemPeriodValue
Reconciling Itemsreconcilingcapex2023-07-01 → 2024-06-30¥798,000
Reconciling Itemsreconcilingdepreciation2023-07-01 → 2024-06-30¥231,000
Reconciling Itemsreconcilingrevenue2023-07-01 → 2024-06-30−¥43m
Reconciling Itemsreconcilingrevenue external2023-07-01 → 2024-06-30¥2m
Reconciling Itemsreconcilingrevenue intersegment2023-07-01 → 2024-06-30−¥44m
Reconciling Itemsreconcilingsegment assetsat 2024-06-30¥1.4bn
Reconciling Itemsreconcilingsegment profit2023-07-01 → 2024-06-30−¥309m
Clinical Evidence Servicereportable segmentcapex2023-07-01 → 2024-06-30¥7m
Clinical Evidence Servicereportable segmentdepreciation2023-07-01 → 2024-06-30¥5m
Clinical Evidence Servicereportable segmentemployeesat 2024-06-3014 pure
Clinical Evidence Servicereportable segmentrevenue2023-07-01 → 2024-06-30¥236m
Clinical Evidence Servicereportable segmentrevenue external2023-07-01 → 2024-06-30¥221m
Clinical Evidence Servicereportable segmentrevenue intersegment2023-07-01 → 2024-06-30¥15m
Clinical Evidence Servicereportable segmentsegment assetsat 2024-06-30¥298m
Clinical Evidence Servicereportable segmentsegment profit2023-07-01 → 2024-06-30−¥70m
Functional Cosmetic Retailingreportable segmentcapex2023-07-01 → 2024-06-30¥6m
Functional Cosmetic Retailingreportable segmentdepreciation2023-07-01 → 2024-06-30¥11m
Functional Cosmetic Retailingreportable segmentemployeesat 2024-06-3027 pure
Functional Cosmetic Retailingreportable segmentrevenue2023-07-01 → 2024-06-30¥1.5bn
Functional Cosmetic Retailingreportable segmentrevenue external2023-07-01 → 2024-06-30¥1.5bn
Functional Cosmetic Retailingreportable segmentsegment assetsat 2024-06-30¥2.6bn
Functional Cosmetic Retailingreportable segmentsegment profit2023-07-01 → 2024-06-30−¥153m
Functional Food Retailingreportable segmentcapex2023-07-01 → 2024-06-30¥310,000
Functional Food Retailingreportable segmentdepreciation2023-07-01 → 2024-06-30¥9m
Functional Food Retailingreportable segmentemployeesat 2024-06-3022 pure
Functional Food Retailingreportable segmentrevenue2023-07-01 → 2024-06-30¥2.5bn
Functional Food Retailingreportable segmentrevenue external2023-07-01 → 2024-06-30¥2.5bn
Functional Food Retailingreportable segmentrevenue intersegment2023-07-01 → 2024-06-30¥10m
Functional Food Retailingreportable segmentsegment assetsat 2024-06-30¥1.0bn
Functional Food Retailingreportable segmentsegment profit2023-07-01 → 2024-06-30−¥158m
Functional Material Developmentreportable segmentdepreciation2023-07-01 → 2024-06-30¥928,000
Functional Material Developmentreportable segmentemployeesat 2024-06-307 pure
Functional Material Developmentreportable segmentrevenue2023-07-01 → 2024-06-30¥318m
Functional Material Developmentreportable segmentrevenue external2023-07-01 → 2024-06-30¥299m
Functional Material Developmentreportable segmentrevenue intersegment2023-07-01 → 2024-06-30¥19m
Functional Material Developmentreportable segmentsegment assetsat 2024-06-30¥1.3bn
Functional Material Developmentreportable segmentsegment profit2023-07-01 → 2024-06-30−¥13m
Health Care Support Servicereportable segmentdepreciation2023-07-01 → 2024-06-30¥353,000
Health Care Support Servicereportable segmentemployeesat 2024-06-309 pure
Health Care Support Servicereportable segmentrevenue2023-07-01 → 2024-06-30¥595m
Health Care Support Servicereportable segmentrevenue external2023-07-01 → 2024-06-30¥595m
Health Care Support Servicereportable segmentsegment assetsat 2024-06-30¥382m
Health Care Support Servicereportable segmentsegment profit2023-07-01 → 2024-06-30¥93m
—segment totalcapex2023-07-01 → 2024-06-30¥13m
—segment totaldepreciation2023-07-01 → 2024-06-30¥27m
—segment totalrevenue2023-07-01 → 2024-06-30¥5.2bn
—segment totalrevenue external2023-07-01 → 2024-06-30¥5.2bn
—segment totalrevenue intersegment2023-07-01 → 2024-06-30¥44m
—segment totalsegment assetsat 2024-06-30¥5.6bn
—segment totalsegment profit2023-07-01 → 2024-06-30−¥301m
Reconciling Itemsreconcilingcapex2022-07-01 → 2023-06-30¥244,000
Reconciling Itemsreconcilingdepreciation2022-07-01 → 2023-06-30¥217,000
Reconciling Itemsreconcilingrevenue2022-07-01 → 2023-06-30−¥25m
Reconciling Itemsreconcilingrevenue external2022-07-01 → 2023-06-30¥2m
Reconciling Itemsreconcilingrevenue intersegment2022-07-01 → 2023-06-30−¥26m
Reconciling Itemsreconcilingsegment assetsat 2023-06-30¥1.5bn
Reconciling Itemsreconcilingsegment profit2022-07-01 → 2023-06-30−¥294m
Clinical Evidence Servicereportable segmentcapex2022-07-01 → 2023-06-30¥8m
Clinical Evidence Servicereportable segmentdepreciation2022-07-01 → 2023-06-30¥4m
Clinical Evidence Servicereportable segmentrevenue2022-07-01 → 2023-06-30¥617m
Clinical Evidence Servicereportable segmentrevenue external2022-07-01 → 2023-06-30¥602m
Clinical Evidence Servicereportable segmentrevenue intersegment2022-07-01 → 2023-06-30¥15m
Clinical Evidence Servicereportable segmentsegment assetsat 2023-06-30¥427m
Clinical Evidence Servicereportable segmentsegment profit2022-07-01 → 2023-06-30¥89m
Functional Cosmetic Retailingreportable segmentcapex2022-07-01 → 2023-06-30¥29m
Functional Cosmetic Retailingreportable segmentdepreciation2022-07-01 → 2023-06-30¥13m
Functional Cosmetic Retailingreportable segmentrevenue2022-07-01 → 2023-06-30¥3.9bn
Functional Cosmetic Retailingreportable segmentrevenue external2022-07-01 → 2023-06-30¥3.9bn
Functional Cosmetic Retailingreportable segmentsegment assetsat 2023-06-30¥3.3bn
Functional Cosmetic Retailingreportable segmentsegment profit2022-07-01 → 2023-06-30¥658m
Functional Food Retailingreportable segmentcapex2022-07-01 → 2023-06-30¥3m
Functional Food Retailingreportable segmentdepreciation2022-07-01 → 2023-06-30¥5m
Functional Food Retailingreportable segmentrevenue2022-07-01 → 2023-06-30¥2.5bn
Functional Food Retailingreportable segmentrevenue external2022-07-01 → 2023-06-30¥2.5bn
Functional Food Retailingreportable segmentsegment assetsat 2023-06-30¥1.3bn
Functional Food Retailingreportable segmentsegment profit2022-07-01 → 2023-06-30¥137m
Functional Material Developmentreportable segmentdepreciation2022-07-01 → 2023-06-30¥1m
Functional Material Developmentreportable segmentrevenue2022-07-01 → 2023-06-30¥501m
Functional Material Developmentreportable segmentrevenue external2022-07-01 → 2023-06-30¥490m
Functional Material Developmentreportable segmentrevenue intersegment2022-07-01 → 2023-06-30¥11m
Functional Material Developmentreportable segmentsegment assetsat 2023-06-30¥1.4bn
Functional Material Developmentreportable segmentsegment profit2022-07-01 → 2023-06-30¥43m
Health Care Support Servicereportable segmentdepreciation2022-07-01 → 2023-06-30¥935,000
Health Care Support Servicereportable segmentrevenue2022-07-01 → 2023-06-30¥553m
Health Care Support Servicereportable segmentrevenue external2022-07-01 → 2023-06-30¥553m
Health Care Support Servicereportable segmentsegment assetsat 2023-06-30¥315m
Health Care Support Servicereportable segmentsegment profit2022-07-01 → 2023-06-30¥93m
—segment totalcapex2022-07-01 → 2023-06-30¥39m
—segment totaldepreciation2022-07-01 → 2023-06-30¥25m
—segment totalrevenue2022-07-01 → 2023-06-30¥8.1bn
—segment totalrevenue external2022-07-01 → 2023-06-30¥8.1bn
—segment totalrevenue intersegment2022-07-01 → 2023-06-30¥26m
—segment totalsegment assetsat 2023-06-30¥6.8bn
—segment totalsegment profit2022-07-01 → 2023-06-30¥1.0bn

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 1,263
ItemContextValueUnit
Capital expenditures overview of capital expenditures etcCurrentYearDuration_jpcrp030000-asr_E05367-000FunctionalCosmeticRetailingReportableSegmentsMember5692000JPY
Number of issued shares as of fiscal year end issued shares total number of shares etcFilingDateInstant_OrdinaryShareMember26158200
Number of issued shares as of filing date issued shares total number of shares etcFilingDateInstant_OrdinaryShareMember26158200
Number of issued shares as of fiscal year end issued shares total number of shares etcFilingDateInstant26158200
Number of issued shares as of filing date issued shares total number of shares etcFilingDateInstant26158200
Number of shares constituting one unitCurrentYearInstant_OrdinaryShareMember100
Number of shareholders national and local governmentsCurrentYearInstant_OrdinaryShareMember-
Number of shareholders financial institutionsCurrentYearInstant_OrdinaryShareMember1
Number of shareholders financial service providersCurrentYearInstant_OrdinaryShareMember22
Number of shareholders other corporationsCurrentYearInstant_OrdinaryShareMember72
Number of shareholders foreign investors other than individualsCurrentYearInstant_OrdinaryShareMember24
Number of shareholders foreign individual investorsCurrentYearInstant_OrdinaryShareMember87
Number of shareholders individuals and othersCurrentYearInstant_OrdinaryShareMember14268
Number of shareholders totalCurrentYearInstant_OrdinaryShareMember14474
Number of shares held number of units national and local governmentsCurrentYearInstant_OrdinaryShareMember-
Number of shares held number of units financial institutionsCurrentYearInstant_OrdinaryShareMember688
Number of shares held number of units financial service providersCurrentYearInstant_OrdinaryShareMember11378
Number of shares held number of units other corporationsCurrentYearInstant_OrdinaryShareMember3218
Number of shares held number of units foreign investors other than individualsCurrentYearInstant_OrdinaryShareMember52710
Number of shares held number of units foreign individual investorsCurrentYearInstant_OrdinaryShareMember834
Number of shares held number of units individuals and othersCurrentYearInstant_OrdinaryShareMember192665
Number of shares held number of units totalCurrentYearInstant_OrdinaryShareMember261493
Number of shares held shares less than one unitCurrentYearInstant_OrdinaryShareMember8900
Percentage of shareholdings national and local governmentsCurrentYearInstant_OrdinaryShareMember-
Percentage of shareholdings financial institutionsCurrentYearInstant_OrdinaryShareMember0.0026
Percentage of shareholdings financial service providersCurrentYearInstant_OrdinaryShareMember0.0435
Percentage of shareholdings other corporationsCurrentYearInstant_OrdinaryShareMember0.0123
Percentage of shareholdings foreigners other than individualsCurrentYearInstant_OrdinaryShareMember0.2016
Percentage of shareholdings foreign individualsCurrentYearInstant_OrdinaryShareMember0.0032
Percentage of shareholdings individuals and othersCurrentYearInstant_OrdinaryShareMember0.7368
Number of shares heldCurrentYearInstant_No1MajorShareholdersMember4625600
Shareholding ratioCurrentYearInstant_No1MajorShareholdersMember0.1768
Number of shares heldCurrentYearInstant_No2MajorShareholdersMember4426800
Shareholding ratioCurrentYearInstant_No2MajorShareholdersMember0.1692
Number of shares heldCurrentYearInstant_No3MajorShareholdersMember356000
Shareholding ratioCurrentYearInstant_No3MajorShareholdersMember0.0136
Number of shares heldCurrentYearInstant_No4MajorShareholdersMember352000
Shareholding ratioCurrentYearInstant_No4MajorShareholdersMember0.0135
Number of shares heldCurrentYearInstant_No5MajorShareholdersMember304700
Shareholding ratioCurrentYearInstant_No5MajorShareholdersMember0.0116
Number of shares heldCurrentYearInstant_No6MajorShareholdersMember220100
Shareholding ratioCurrentYearInstant_No6MajorShareholdersMember0.0084
Number of shares heldCurrentYearInstant_No7MajorShareholdersMember180700
Shareholding ratioCurrentYearInstant_No7MajorShareholdersMember0.0069
Number of shares heldCurrentYearInstant_No8MajorShareholdersMember180000
Shareholding ratioCurrentYearInstant_No8MajorShareholdersMember0.0069
Number of shares heldCurrentYearInstant_No9MajorShareholdersMember177200
Shareholding ratioCurrentYearInstant_No9MajorShareholdersMember0.0068
Number of shares heldCurrentYearInstant_No10MajorShareholdersMember167000
Shareholding ratioCurrentYearInstant_No10MajorShareholdersMember0.0064

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 24 of 24 passed
balance sheet identityconsolidated 2023-06-30pass rounding
balance sheet identityconsolidated 2024-06-30pass rounding
balance sheet identitynon_consolidated 2023-06-30pass rounding
balance sheet identitynon_consolidated 2024-06-30pass
dei present pass
period resolution pass
statement vs summary · net assetsconsolidated 2022-06-30pass
statement vs summary · net assetsconsolidated 2023-06-30pass
statement vs summary · net assetsconsolidated 2024-06-30pass
statement vs summary · net assetsnon_consolidated 2022-06-30pass
statement vs summary · net assetsnon_consolidated 2023-06-30pass
statement vs summary · net assetsnon_consolidated 2024-06-30pass
statement vs summary · net income attributable to parentconsolidated 2022-07-01/2023-06-30pass
statement vs summary · net income attributable to parentconsolidated 2023-07-01/2024-06-30pass
statement vs summary · operating cash flowconsolidated 2022-07-01/2023-06-30pass
statement vs summary · operating cash flowconsolidated 2023-07-01/2024-06-30pass
statement vs summary · revenueconsolidated 2022-07-01/2023-06-30pass
statement vs summary · revenueconsolidated 2023-07-01/2024-06-30pass
statement vs summary · revenuenon_consolidated 2022-07-01/2023-06-30pass
statement vs summary · revenuenon_consolidated 2023-07-01/2024-06-30pass
statement vs summary · total assetsconsolidated 2023-06-30pass
statement vs summary · total assetsconsolidated 2024-06-30pass
statement vs summary · total assetsnon_consolidated 2023-06-30pass
statement vs summary · total assetsnon_consolidated 2024-06-30pass